Nektar Therapeutics released data from a study of its rezpegaldesleukin drug, establishing proof-of-concept in patients with severe to very severe alopecia areata, a hair-loss condition.

Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...

US biotech Nektar Therapeutics shares increased by 10% in pre-market trading following promising Phase IIb trial results.

Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...

Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...

Nektar Therapeutics (NASDAQ:NKTR) reported results from its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata, with the trial narrowly ...

Shares of Nektar Therapeutics NKTR have rallied 38.2% in the past week due to growing investor optimism related to the company’s lead pipeline candidate, rezpegaldesleukin (rezpeg), which is being ...

Alopecia areata causes hair loss on the scalp or other body parts such as the eyebrows. New treatments like Olumiant offer hope for some people. This FDA-approved medicine works in unique ways to help ...

The U.S. FDA has approved Sun Pharmaceutical Industries Ltd.’s Leqselvi (deuruxolitinib), a JAK1 and JAK2 inhibitor for adults with severe alopecia areata, a chronic autoimmune disease. The ...